论文部分内容阅读
目的探讨多西他赛联合奥沙利铂和吉西他滨联合奥沙利铂在晚期食管鳞癌患者治疗方面的临床价值差异。方法在2014年9月—2016年2月期间许昌市中心医院收治的晚期食管鳞癌患者中选取76例,将其分为吉西他滨组和多西他赛组,对两组患者的临床治疗效果及其毒副反应发生情况进行观察分析。结果吉西他滨组和多西他赛组患者的食管癌客观缓解率(57.14%、53.57%)、疾病控制率(82.14%、82.14%)相比并无明显差异(P>0.05);吉西他滨组患者治疗期间恶心呕吐、粒细胞减少、肌肉酸痛、末梢神经麻木的发生率均明显低于多西他赛组,血小板减少发生率则明显高于后者,差异具有显著性(P<0.05)。结论多西他赛与吉西他滨分别联合奥沙利铂均可有效治疗晚期食管鳞癌患者,有助于促进患者生活质量的提高及其生存时间的延长,但其中吉西他滨联合奥沙利铂在降低患者毒副反应方面表现更加,有助于提高患者治疗耐受性。
Objective To investigate the clinical value of docetaxel in combination with oxaliplatin and gemcitabine plus oxaliplatin in the treatment of patients with advanced esophageal squamous cell carcinoma. Methods Seventy-six patients with advanced esophageal squamous cell carcinoma who were treated in Xuchang Central Hospital between September 2014 and February 2016 were divided into gemcitabine group and docetaxel group. The occurrence of toxic reactions observed and analyzed. Results The objective response rates (57.14%, 53.57%) and disease control rates (82.14%, 82.14%) in gemcitabine group and docetaxel group were not significantly different (P> 0.05). Gemcitabine group Nausea and vomiting, neutropenia, muscle soreness, peripheral nerve numbness were significantly lower than docetaxel group, the incidence of thrombocytopenia was significantly higher than the latter, the difference was significant (P <0.05). Conclusion Docetaxel combined with gemcitabine combined with oxaliplatin respectively can effectively treat patients with advanced esophageal squamous cell carcinoma and promote the improvement of patients ’quality of life and the prolongation of their survival time. However, gemcitabine combined with oxaliplatin can reduce the patients’ More toxic side effects, helping to improve patient tolerability.